
Visceral Fat, Reduced
Randomized trials found meaningful reductions in visceral fat.
FDA-approved for a complication of HIV treatment. Prologue prescribes it off-label, and it raises blood sugar.
Tesamorelin is a growth hormone releasing hormone analog. The FDA approved it in 2010 as Egrifta, to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. Prologue prescribes it off-label.
It prompts the pituitary to release growth hormone in its natural rhythm, which raises IGF-1. Growth hormone influences how the body stores fat, which is where the body-composition interest comes from.
Two effects need checking before your physician will prescribe it: it raises blood sugar, and it raises IGF-1.

Randomized trials found meaningful reductions in visceral fat.

Daily subcutaneous injection.

FDA-approved for a complication of HIV treatment. Prologue prescribes it off-label.
A consultation with a Prologue physician.
Your A1c, your fasting glucose, and your cancer history.
FDA-approved for a complication of HIV treatment. Prologue prescribes it off-label.
Daily subcutaneous injection, compounded by a licensed pharmacy partner.
The evidence comes from randomized trials in people with HIV-associated lipodystrophy, which found meaningful reductions in visceral fat.
Egrifta · FDA-approved 2010
No trial has been run on healthy adults taking it for body composition. The mechanism should work the same way. Whether it works as well is unknown.
The visceral fat returns when you stop taking it.

Growth hormone raises glucose, and tesamorelin raises growth hormone. In the approved trials it worsened glucose control in some people. Your physician checks your A1c and fasting glucose before prescribing.

Growth hormone and IGF-1 are growth signals. Active malignancy is a contraindication on the approved label. Whether long-term IGF-1 elevation affects cancer risk over decades remains an open question in the literature, and your physician will weigh your family history against it.
These two risks are specific to tesamorelin. The consultation also covers your full medical history, and your physician may ask for recent lab results depending on what they find.

Daily subcutaneous injection.
There's no established dose for the off-label use. Your physician sets it against your lab results, including IGF-1, and adjusts.
Compounded by a licensed pharmacy partner and tested for potency, sterility, and endotoxin levels before shipment.
Tesamorelin is FDA-approved as Egrifta for the reduction of excess visceral abdominal fat in patients with HIV-associated lipodystrophy. Prologue prescribes it off-label for longevity indications. It is compounded by a licensed pharmacy partner and tested for potency, sterility, and endotoxin levels before shipment. Treatment is not appropriate for every patient, and outcomes vary. Talk with your physician about whether this fits your situation.
Tesamorelin requires a consultation with a Prologue physician.
Everyone else starts by joining the practice.
Members can bring it up at their next consultation.
Not listed here? Read the full FAQ.